Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00216749
Status:
COMPLETED
Last Update Posted:
2009-12-17
First Post:
2005-09-14
Brief Title:
Efficacy and Safety of Cilostazol for the Indication of CSPS
Sponsor:
Korea Otsuka Pharmaceutical Co Ltd
Organization:
Korea Otsuka Pharmaceutical Co Ltd
Study Overview
Official Title:
Post Marketing Surveillance of Efficacy and Safety of Cilostazol for the Indication of CSPS
Status:
COMPLETED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter open-label prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction
Detailed Description:
This is a multicenter open-label prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction
Qualified patients will be treated with cilostazol by physicians assessment This study will be continued for 4 years More than 600 patients for 4 years
Qualified patients will be treated with cilostazol by physicians assessment This study will be continued for 4 years More than 600 patients for 4 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None